All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 19, 2022
Home » Topics » Immune, BioWorld

Immune, BioWorld
Immune, BioWorld RSS Feed RSS

Summer stock: Atara shares await July review of phase II MS trial

May 13, 2022
By Randy Osborne
No Comments
As the six-month interim analysis of phase II data for ATA-199 in progressive forms of multiple sclerosis (MS) nears, investors in Atara Biotherapeutics Inc. – not to mention patients – are growing more intrigued by the prospect, an off-the-shelf T-cell candidate that targets Epstein Barr virus-infected B cells and plasma cells in the central nervous system.
Read More

Mooted reverse merger with Medsenic a lifeline for Bone Therapeutics

May 12, 2022
By Cormac Sheridan
No Comments
Bone Therapeutics SA has entered an exclusive three-month discussion period with Medsenic SAS, which could culminate in a reverse merger. The potential transaction represents a lifeline for the troubled Belgian cell therapy developer, which is running out of cash and which has been more or less abandoned by its shareholders.
Read More
Pamela Conley, CEO, Nuvig
Newco news

‘Stable’ door opens for Nuvig as $47M series A backs homeostasis bid

May 11, 2022
By Randy Osborne
No Comments
Nuvig Therapeutics Inc. emerged from stealth mode with a $47 million series A round to back efforts to develop drugs that induce immune homeostasis as a way of treating autoimmune diseases without disturbing the system’s normal function.
Read More
Hands holding gears

Amphista lands potentially rich deals with Merck, BMS

May 4, 2022
By Lee Landenberger
No Comments
Privately held Amphista Therapeutics Ltd. has cut massive deals with two biopharma giants, Merck KGaA and Bristol Myers Squibb Co. (BMS), that together could bring the company up to $2.25 billion. The companies will use Amphista’s Eclipsys platform to generate protein degrader-based therapeutics. Merck is looking to discover and develop small-molecule protein degraders for treating cancer and immune disease. Indications in the BMS deal were not announced.
Read More
Flower with dollar sign

Dianthus blossoms with $100M series A round to target complement system

May 3, 2022
By Cormac Sheridan
No Comments
Dianthus Therapeutics Inc. has, appropriately, flowered in springtime. The Waltham, Mass.-based company emerged from stealth with $100 million in series A funding and lofty ambitions to rewrite the rules of targeting the complement system with a pipeline of antibodies that bring new levels of selectivity to an area of innate immunity that has proved difficult to target.
Read More
Inflammation illustration

Innate immune memory underlies inflammatory comorbidities: study

May 2, 2022
By Anette Breindl
No Comments
Researchers at the University of Pennsylvania have gained new insight into how different inflammatory conditions reinforce each other via trained innate immunity.
Read More
Back and shoulder

As LS tree line rises, Timber stacked for success?

April 29, 2022
By Randy Osborne
No Comments
A handful of developers are advancing drug prospects in the localized scleroderma (LS) space, with candidate mechanisms that range from cell-based gene therapy to IL-4 or IL-6 antagonism to PDE4 blocking, and with efforts that involve approved as well as experimental compounds.
Read More
Dollar sign in light bulb on yellow background

Cimeio ‘points’ the way to safer cell therapy with $50M series A round

April 13, 2022
By Cormac Sheridan
No Comments
Versant Ventures is committing $50 million in series A funding to Cimeio Therapeutics Inc., which aims to bring new possibilities in terms of disease targeting and safety to bear on a wide range of cell therapy applications, including hematopoietic stem cell transplantation (HSCT) and adoptive cell transfer.
Read More

Single-patient data suggest Tiziana nose a better way with CD3 in MS

March 15, 2022
By Randy Osborne
No Comments
Tiziana Life Sciences Inc.’s intranasal, fully human anti-CD3 monoclonal antibody will need testing in 10 or 20 more patients to confirm the signal in secondary progressive multiple sclerosis (SPMS), but key opinion leaders on a conference call March 14 sounded optimistic as they checked out the prospect’s early efficacy.
Read More

Conference data for Feb. 28, 2022: AAAAI

Feb. 28, 2022
No Comments
New and updated preclinical and clinical data presented by biopharma firms at the ASCO Genitourinary Cancers Symposium, including: Amgen, Knopp, Regeneron, Sanofi.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 16 17 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 18, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 18.
  • China U.S. deal

    Merck acquires global rights to cancer drug from Kelun in $1.4B deal

    BioWorld
    In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing